文献类型：期刊文献

中文题名：半夏泻心汤加味治疗萎缩性胃炎胃癌前病变的疗效及其对TGF-β1/Smads信号通路的影响

英文题名：Modified Banxia Xiexin decoction for treatment of precancerous lesions of atrophic gastritis:Efficacy and influence on TGF-β1/Smads signaling pathway

作者：李莉[1];陈俊寅[2];胡玲琴[1];卢珊珊[1];吕秋琼[3];尉理梁[4]

机构：[1]绍兴文理学院附属医院老年医学科,浙江省绍兴市312000;[2]绍兴文理学院附属医院消化内科,江省绍兴市312000;[3]绍兴文理学院附属医院检验科,浙江省绍兴市312000;[4]绍兴文理学院附属医院中医科,浙江省绍兴市312000

年份：2021

卷号：29

期号：6

起止页码：291

中文期刊名：世界华人消化杂志

外文期刊名：World Chinese Journal of Digestology

收录：Scopus

语种：中文

中文关键词：萎缩性胃炎;胃癌前病变;半夏泻心汤加味;疗效;症状评分

外文关键词：Atrophic gastritis;Precancerous lesion of gastric cancer;Modified Banxia Xiexin decoction;Curative effect;Symptom score

中文摘要：背景本研究通过分析半夏泻心汤加味治疗慢性萎缩性胃炎(chronic atrophic gastritis,CAG)胃癌前病变的疗效,通过TGF-β/smads信号转导通路,进一步探索半夏泻心汤加味治疗CAG胃癌前病变的临床效果,以为临床治疗提供依据.目的探讨半夏泻心汤加味治疗萎缩性胃炎胃癌前病变的疗效及其对TGF-β1/Smads信号通路的影响.方法选取2019-01/2020-01我院收治的慢性萎缩性胃炎CAG癌前病变患者89例为研究对象,将入选患者随机分为对照组(n=44)和实验组(n=45),对照组给予常规治疗+中成药胃复春片,实验组在常规治疗基础上联合半夏泻心汤加味治疗,比较两组患者治疗前后临床症状改善评分、血清因子(包括TGF-β1、smad1、smad2)、病理积分及临床疗效的差异.结果治疗后,实验组患者胃痛胃胀、胃脘痞满、食少纳呆、神疲乏力等临床症状评分明显低于对照组及同组治疗前,比较差异具有统计学意义(P<0.05).治疗后,实验组患者胃黏膜活检组织中Smad1、Smad2、TGF-β1蛋白的阳性率明显低于对照组和治疗前(P<0.05).治疗后,实验组患者胃黏膜活检组织中Smad1蛋白表达量及mRNA的相对含量明显高于对照组和同组治疗前(P<0.05),而TGF-β1、Smad2蛋白表达量及mRNA的相对含量明显低于对照组和同组治疗前(P<0.05).治疗后,实验组萎缩、肠上皮化生、异型增生等病理积分均明显低于对照组及同组治疗前,比较差异具有统计学意义(P<0.05).实验组治疗总有效率88.89%明显高于对照组59.09%,比较差异具有统计学意义(P<0.05).结论半夏泻心汤加味药方具有平调寒热、辛开苦降之功效,治疗CAG胃癌前病变可以改善患者临床症状,疗效较好,可以延缓胃癌前病变的进一步进展.

外文摘要：BACKGROUND This study analyzed the efficacy of modified Banxia Xiexin decoction in the treatment of precancerous lesions of chronic atrophic gastritis(CAG)and its effect on the TGF-β/Smads signal transduction pathway,so as to provide a basis for clinical treatment of CAG.AIM To evaluate the efficacy of modified Banxia Xiexin decoction in the treatment of CAG precancerous lesions and its influence on the TGF-β1/Smads signaling pathway.METHODS Eighty-nine patients with CAG precancerous lesions treated at our hospital from January 2019 to January 2020 were included and randomly divided into either a control group(n=44)or an experimental group(n=45).The control group was given conventional treatment plus Weifuchun tablets.The experimental group was treated with Banxia Xiexin decoction on the basis of conventional treatment.The clinical symptom improvement score,serum factors(including TGF-β1,Smad1,and Smad2),pathological score,and clinical efficacy were compared between the two groups.RESULTS After treatment,the scores of clinical symptoms such as stomachache and distension,epigastric distension,lack of appetite,and fatigue in the experimental group were significantly lower than those before treatment and those in the control group(P<0.05);the positive rates of Smad1,Smad2,and TGF-β1 proteins in gastric mucosal biopsy tissue in the experimental group were significantly lower than those before treatment and those in the control group(P<0.05);and the relative contents of Smad1 protein and mRNA in gastric mucosal biopsy tissues in the experimental group were significantly higher than those before treatment and those in the control group(P<0.05),while the relative contents of TGF-β1 and Smad2 proteins and mRNA were significantly lower than those before treatment and those in the control group(P<0.05).The total effective rate of the experimental group was 88.89%,which was significantly higher than that of the control group(59.09%;P<0.05).CONCLUSION Modified Banxia Xiexin decoction can improve the clinical symptoms of patients with CAG precancerous lesions,and delay the further progression of the precancerous lesions.